Tempus AI, Inc. (NASDAQ:TEM) Given Average Recommendation of “Moderate Buy” by Brokerages

Tempus AI, Inc. (NASDAQ:TEMGet Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $56.00.

Several equities analysts have recently weighed in on the stock. Loop Capital lifted their target price on shares of Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Guggenheim assumed coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target for the company. Finally, Wolfe Research initiated coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock.

Read Our Latest Analysis on TEM

Tempus AI Stock Performance

Shares of TEM stock opened at $33.87 on Tuesday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The business’s 50 day moving average is $50.06. Tempus AI has a 12-month low of $22.89 and a 12-month high of $79.49.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the completion of the sale, the chief executive officer now owns 9,557,283 shares of the company’s stock, valued at $358,780,403.82. The trade was a 1.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 845,041 shares of company stock valued at $35,125,473.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Kovitz Investment Group Partners LLC bought a new position in Tempus AI during the 3rd quarter worth approximately $1,367,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares during the period. Captrust Financial Advisors bought a new position in shares of Tempus AI in the third quarter worth approximately $2,726,000. Sigma Planning Corp purchased a new position in shares of Tempus AI in the third quarter worth $1,323,000. Finally, Dakota Wealth Management bought a new stake in Tempus AI during the 3rd quarter valued at $1,185,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

(Get Free Report

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Featured Stories

Analyst Recommendations for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.